Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, share considerations for sequencing CAR T-cell therapies in patients with LBCL, depending on treatments they have already received.
Cell and Gene Therapy Trials Face Disproportionate Amount of Clinical Holds
Oncological trials of biologics also face particularly higher rates of clinical holds.
CGTLive®’s Weekly Rewind – May 17, 2024
Review top news and interview highlights from the week ending May 17, 2024.
Verismo Therapeutics’ CAR-T SynKIR-310 Cleared for Trial in R/R B-NHL
Verismo intends to go forward with plans for the phase 1 CELESTIAL-301 clinical trial, which the company expects to initiate in the second half of this year.
Considerations for Gene Therapy Logistics and Implementation
Omer A. Abdul Hamid, MD, pediatric neurologist at Nemours Children’s Health offered advice and discussed important practical considerations with administering gene therapies.
Liso-Cel/Breyanzi Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The CAR T-cell therapy was also recently approved for treating chronic lymphocytic leukemia or small lymphocytic lymphoma.
Around the Helix: Cell and Gene Therapy Company Updates – May 15, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.